Inflammatory Bowel Disease

Damas explains what inspired her research about the impact of a low-calorie plant-based diet on clinical response to medication in patients with ulcerative colitis.

The MyGut digital health monitoring platform proves feasible and impactful during integration into inflammatory bowel disease care.

Dubinsky explains the disconnect between patients with Crohn disease and health care providers regarding the impact of and importance of addressing bowel urgency.

Experts discuss the warnings regarding IL-17 blockers and inflammatory bowel disease.

Incident use of anti-TNF therapy was linked to an increased risk of kidney function decline but not all-cause mortality in patients with newly diagnosed IBD.

Findings demonstrate a similar postoperative safety profile for both tofacitinib and biologics in patients with medically refractory ulcerative colitis undergoing colectomy.

Findings highlight the negative impact of bowel urgency and bowel urgency-related accidents on the daily lives of patients with UC and CD.

Qazi discusses tofacitinib’s role in acute severe ulcerative colitis management as a potential first-line therapy to increase treatment responsiveness.

Psoriatic arthritis and spondyloarthritis occurred earlier in children and adolescents with IBD than in the matched references without IBD.

Test your knowledge of the AGA Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases with this clinical quiz!

Our February 2024 month in review highlights EoE pipeline news, new FMT guidelines, and research about endoscopic inflammation and disease activity in IBD.

Inflammatory markers, infliximab levels, and physician global assessment scores remained similar when assessed pre- and post-switch to an infliximab biosimilar.

Dubinsky discusses the importance of head-to-head trials in IBD and looks ahead to the use of combination therapy to achieve desired treatment outcomes.

Dubinsky discusses findings from a post-hoc analysis of the head-to-head SEQUENCE trial of risankizumab versus ustekinumab in patients with Crohn disease refractory to anti-TNF therapy.

Investigators from the guideline panel discuss the AGA’s recommendations regarding the use of fecal microbiota-based therapies for CDI, IBD, and IBS.

The guideline recommends fecal microbiota transplant in most cases of recurrent Clostridioides difficile infection but does not suggest fecal microbiota-based therapies for IBD or IBS.

Histological inflammation and clinical IBD activity were both associated with reduced fertility rates compared to histological remission and quiescent IBD.

Experts in gastroenterology discuss treatment selection in special situations of CD, such as age, women considering pregnancy, and extra-intestinal manifestations.

Remo Panaccione, MD, FRCPC, provides an overview of the newest oral therapy approved for CD, upadacitinib.

David Rubin, MD, leads the panel discussion on a head-to-head sequence study of rizankizumab vs ustekinumab in the treatment of CD, as well as approaches to choosing first-line treatment.

Marla Dubinsky, MD, discusses the use of off-label upadacitinib in pediatric IBD patients and the importance of this research due to delays in pediatric drug approvals.

Marla Dubinsky, MD, discusses the use of segmental intestinal ultrasound to address screen failure associated with the SES-CD in clinical trials and for detecting transmural healing.

David Rubin, MD, reviews the use of IL-12 and IL-23 inhibitors in the treatment of CD, highlighting ustekinumab and risankizumab for first-line therapy and beyond.

Experts in gastroenterology provide an overview of anti-TNF (tumor necrosis factor) and anti-integrin therapies in treatment of CD.

Patients who switched from originator adalimumab to a biosimilar experienced more treatment-emergent adverse events compared to those who stuck with the biosimilar or the reference drug.

Sara Horst, MD, MPH, and Miguel Regueiro, MD, comment on the changing treatment landscape of CD, as well as share approaches to communicate with patients about starting biologic treatment early on in CD.

Experts in gastroenterology share approaches to engaging patients in achieving treatment targets beyond symptom control.

A high intake of fish and vegetables at 1 year of age was associated with a lower risk of IBD, while consuming sugar-sweetened beverages was linked to a greater risk of developing IBD.

Experts continue the discussion on treat-to-target in CD, highlighting monitoring treatment response.

Miguel Regueiro, MD, and David Rubin, MD, review the treat-to-target strategy in relation to CD management, and how treat-to-target moves beyond symptom control.